Telluride Premiere Shows Unprecedented Holmes Access

A Secret Film Stuns Telluride

A three‑hour cut of “You Can See Everything” landed at the Telluride Film Festival on Sunday night, leaving the audience buzzing. The film is the first public glimpse of Elizabeth Holmes moving freely just 34 days before she reports to prison.

The documentary is the work of comedians‑turned‑filmmakers Nathan Fielder and Lance Oppenheim. Their crew followed Holmes for three years, capturing her daily routines, investor calls, and moments that feel almost rehearsed. The festival premiere was a surprise screening; no press release preceded it, and the audience learned the title only moments before the lights dimmed.

What the Camera Catches

Fielder and Oppenheim secured unprecedented access after Holmes agreed to let a skeptical crew document her every move. The film shows her rehearsing speeches, scrolling through old Theranos emails, and strolling through a quiet Texas suburb. In one scene, Holmes pauses at a kitchen counter, picks up a glass of water, and looks directly into the lens as if asking the viewer for forgiveness.

The filmmakers also recorded Holmes’s interactions with former advisors, including a brief encounter with Channing Robertson, the Stanford professor who quit his tenure to back Theranos. The footage does not shy away from the oddities: Holmes practices a half‑smile while describing the Edison device, a countertop blood‑testing box that she claimed could run 200 tests on a finger‑prick sample. The camera captures the dissonance between her polished pitch and the cramped lab spaces she walks through.

A Different Lens Than “The Inventor”

Alex Gibney’s HBO documentary, “The Inventor: Out for Blood in Silicon Valley,” premiered at Sundance and later aired on March 18. Gibney never sat down with Holmes; the film relies on archival footage, interviews with journalists like John Carreyrou, and testimonies from former Theranos employees such as Tyler Shultz and Erika Cheung. Critics note that while Gibney’s film lacks new visual material, it excels at explaining how Holmes built a $9 billion valuation on a flawed micro‑fluidics premise.

“You Can See Everything” flips that script. Instead of a forensic deconstruction, it offers a portrait that feels almost intimate. The audience watches Holmes repeat the same anecdote about her uncle’s early death from undetected cancer, a story she used to justify the urgency of her blood‑testing mission. The new film does not provide the same breadth of expert analysis that Gibney’s work does, but it gives viewers a sense of Holmes’s personal charisma and the performative aspect of her leadership.

Why This Matters Now

The timing is stark. Holmes is slated to begin a 11‑month federal prison term in early November. The documentary captures her in the final stretch of pre‑sentencing life, a period rarely documented for high‑profile fraudsters. The footage may become a primary source for future scholars examining how a charismatic founder can sustain a multi‑billion‑dollar empire on a technically impossible promise.

Moreover, the film arrives amid a wave of tech‑industry retrospectives. From the rise of AI startups to renewed scrutiny of venture capital due diligence, the Theranos saga remains a cautionary tale. By allowing Holmes to speak directly to the camera, Fielder and Oppenheim force the industry to confront the human side of deception—not just the broken technology, but the personal ambition that drove it.

The Broader Documentary Trend

Both documentaries illustrate a shift in how the tech world tells its own cautionary stories. Earlier portrayals, such as the 2019 Netflix series “Bad Blood,” leaned heavily on dramatized reenactments. Today, filmmakers are either digging into archives (Gibney) or embedding themselves for months (Fielder/Oppenheim). The result is a richer, more nuanced narrative that resists easy moralizing.

The Telluride screening also signals a growing appetite for “access‑first” storytelling. Audiences seem eager for raw footage that lets them draw their own conclusions, rather than being handed a pre‑packaged verdict. This approach aligns with the tech community’s preference for data over commentary; viewers can see the same clip of Holmes discussing the Edison device and decide whether the pitch was persuasive or delusional.

What to Watch Next

The next data point to track is the documentary’s distribution plan. If a streaming platform picks up “You Can See Everything,” the film could reach a broader audience and potentially influence public opinion ahead of Holmes’s sentencing hearing. Additionally, watch for any legal challenges from Theranos’s former investors or the SEC, who may argue that the film reveals privileged information. Finally, monitor how the film is cited in academic and industry analyses of founder fraud; its primary‑source footage could become a cornerstone for future case studies.

By Ryan Tanaka